Login to Your Account

JPM 2015

Abbvie CFO downplays HCV pricing drama

By Michael Fitzhugh
Staff Writer

Wednesday, January 14, 2015

SAN FRANCISCO – Abbvie Inc.'s chief financial officer, Bill Chase, said competition for market share and the pricing saga playing out between its new HCV therapy, Viekira Pak and Gilead Sciences Inc.'s Harvoni is "exactly what we expected," but that the media's focus on price has been much heavier than merited.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription